SPIKENET: An Evidence-Based Therapy for Long COVID

Area of Science:

• Virology
• Immunology
• Drug Discovery

Background:

• COVID-19 pandemic caused by SARS-CoV-2 has led to long COVID (PASC) with no current treatments.
• Both vaccinated and unvaccinated individuals experience long-term complications.
• Existing SARS-CoV-2 variants pose ongoing global health challenges.

Purpose of the Study:

• To introduce a novel synthetic peptide, SPIKENET (SPK), as a potential therapeutic agent for COVID-19.
• To investigate SPK's mechanism of action against SARS-CoV-2 and other coronaviruses.
• To evaluate SPK's efficacy in preclinical models of viral infection.

Main Methods:

• Designed a 15-amino-acid synthetic peptide (SPK) targeting the ACE2 receptor binding domain of SARS-CoV-2.
• Tested SPK's ability to inhibit binding of spike glycoproteins to ACE2 and CEACAM1.
• Assessed SPK's therapeutic effects in mouse models infected with murine hepatitis virus-1 (MHV-1).

Main Results:

• SPK effectively blocked SARS-CoV-2 attachment to the host ACE2 receptor and inhibited spike glycoprotein binding to CEACAM1 in MHV-1.
• SPK reversed severe inflammation, oxidative stress, tissue edema, and mortality in MHV-1 infected mice.
• SPK demonstrated protective effects against acute and long-term multi-organ damage in the MHV-1 mouse model.

Conclusions:

• SPIKENET (SPK) presents a potential therapeutic strategy for COVID-19 by preventing viral entry.
• SPK shows broad efficacy against SARS-CoV-2 variants and other coronaviruses.
• Preclinical data suggest SPK could be a valuable treatment for acute COVID-19 and long COVID complications.